The Pulmonary Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Pulmonary Hypertension Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Hypertension Market.
Some of the key takeaways from the Pulmonary Hypertension Pipeline Report:
- Companies across the globe are diligently working toward developing novel Pulmonary Hypertension treatment therapies with a considerable amount of success over the years.
- Pulmonary Hypertension companies working in the treatment market are Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutics, Pharmosa Biopharm, Merck, Arena Pharmaceuticals/United Therapeutics, Bial – Portela C S.A., Respira Therapeutics, Gmax Biopharm, Aerami Therapeutics, Centessa Pharmaceuticals, and others, are developing therapies for the Pulmonary Hypertension treatment
- Emerging Pulmonary Hypertension therapies in the different phases of clinical trials are- TOP V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, L606, Sotatercept, Ralinepag, Zamicastat, RT234, GMA301, AER-901, MGX 292, and others are expected to have a significant impact on the Pulmonary Hypertension market in the coming years.
- In July 2022, The Phase II research for the medication candidate CS1 for pulmonary arterial hypertension (PAH) has begun, according to a report from Cereno Scientific. The study’s timeframe has been modified by nearly a quarter, and top-line results are now anticipated for Q1 2023 based on the timing of enrolment and a number of variables, most of which are connected to the activation of clinical sites. To help achieve the Q1 deadline, the number of study sites has been increased to include around 10 clinics across the US, with room for future growth.
- In June 2022, Key preclinical data confirming seralutinib’s potential for the treatment of pulmonary arterial hypertension (PAH) were published, according to a statement from Gossamer Bio, Inc. With improved cardiac hemodynamics, decreased NT-proBNP, reverse remodelling of pulmonary vascular disease, and improved inflammatory biomarkers, inhaled seralutinib was an effective treatment for severe PAH in two animal models. In a preclinical research, seralutinib outperformed imatinib in terms of efficacy.
- In June 2022, At the Pulmonary Hypertension Association International Conference and Scientific Sessions, which took place from June 10 through 12, 2022, Keros Therapeutics, Inc. presented findings from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arterial hypertension (“PAH”).
- In June 2022, As a potentially life-saving treatment for patients with acute pulmonary hypertension following cardiac surgery, Attgeno AB recently announced that it had received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to begin a phase 2 clinical trial of its lead drug candidate Supernitro.
- In May 2022, At the American Thoracic Society (ATS) International Conference in San Francisco, Aerovate Therapeutics, Inc. presented Phase 1 findings. According to Aerovate’s research, AV-101, a brand-new imatinib inhalation dry powder formulation, was generally well tolerated by healthy adult volunteers. No major side effects were noted. As important aspects of the pathogenesis of PAH, cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature are being addressed by the development of AV-101.
- In May 2022, Results from an animal model of pulmonary arterial hypertension (PAH) that compared rodatristat ethyl as a monotherapy and in conjunction with the type A endothelin receptor antagonist, ambrisentan, were presented by Altavant Sciences. At ATS 2022, which was held in San Francisco, California, from May 13–18, 2022, results detailing changes in post-hypoxia occlusions and mean pulmonary arterial pressure (mPAP) with each treatment regimen were presented in a poster.
- In April 2022, The multicenter trial of Respira Therapeutics‘ principal product candidate, RT234-PAH (vardenafil delivered as a dry powder inhalation therapy), saw the first patient in the United States receive a dosage. Two successive cohorts of the VIPAH-PRN 2b trial (Vardenafil Inhaled for Pulmonary Arterial Hypertension – PRN) will be given single doses of RT234 via an Axial Oscillating Sphere dry powder inhaler. The objective of the trial is to assess the safety and preliminary efficacy of RT234 in treating PAH patients with New York Heart Association (NYHA) Functional Class II–III symptoms for acutely improving episodic symptoms and exercise capacity.
- In March 2022, An study titled “BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study” was published in the esteemed American Journal of Respiratory and Critical Care Medicine, according to a press release from Resverlogix Corp. The article describes apabetalone’s beneficial effects in the investigator-led APPRoAcH-p pilot research for pulmonary arterial hypertension (PAH).
- In March 2022, In order to assess the effectiveness of Sotatercept when combined with background pulmonary arterial hypertension (PAH) therapy in newly diagnosed intermediate- and high-risk PAH patients, Acceleron Pharma began a Phase 3 randomised, double-blind, placebo-controlled research.
- In November 2021, The successful completion of the acquisition of Acceleron Pharma Inc. was announced by Merck, also known as MSD outside of the United States and Canada.
Pulmonary Hypertension Overview
Elevated pulmonary vascular resistance is a defining characteristic of the broad group of illnesses known as pulmonary hypertension. Patients frequently exhibit vague symptoms such as increasing weakness and dyspnea with exertion. The management of symptoms and the therapy of underlying disorders are the main goals of treatment for the progressive disease known as pulmonary hypertension.
Get a Free Sample PDF Report to know more about Pulmonary Hypertension Pipeline Therapeutic Assessment-
Emerging Pulmonary Hypertension Drugs Under Different Phases of Clinical Development Include:
- TOP V122: Topadur Pharma
- MGX292: Centessa Pharmaceuticals
- RBM-011: Ribomic
- Getagozumab: Gmax Biopharm
- NTP42: ATXA Therapeutics
- AER-901: Aerami Therapeutics
- Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
- Rodatristat Ethyl: Altavant Sciences
- RT234: Respira Therapeutics
- L606: Pharmosa Biopharm
- Sotatercept: Merck
- Ralinepag: Arena Pharmaceuticals/United Therapeutics
- Zamicastat: Bial – Portela C S.A.
- RT234: Respira Therapeutics
- GMA301: Gmax Biopharm
- AER-901: Aerami Therapeutics
- RBM-011: Ribomic
- MGX 292: Centessa Pharmaceuticals
Pulmonary Hypertension Route of Administration
Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Pulmonary Hypertension Molecule Type
Pulmonary Hypertension Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
Pulmonary Hypertension Pipeline Therapeutics Assessment
- Pulmonary Hypertension Assessment by Product Type
- Pulmonary Hypertension By Stage and Product Type
- Pulmonary Hypertension Assessment by Route of Administration
- Pulmonary Hypertension By Stage and Route of Administration
- Pulmonary Hypertension Assessment by Molecule Type
- Pulmonary Hypertension by Stage and Molecule Type
DelveInsight’s Pulmonary Hypertension Report covers around 80+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Pulmonary Hypertension product details are provided in the report. Download the Pulmonary Hypertension pipeline report to learn more about the emerging Pulmonary Hypertension therapies
Some of the key companies in the Pulmonary Hypertension Therapeutics Market include:
Key companies developing therapies for Pulmonary Hypertension are – Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, Abraxis Bioscience, Bayer, Novartis, Aerovate Therapeutics, Cereno Scientific AB, Gossamer Bio, Altavant Sciences GmbH, Gmax Biopharm LLC., Respira Therapeutics, Resverlogix Corp, Aerami Therapeutics, Vigonvita Life Sciences, Ribomic, Corsair Pharma, Centessa Pharmaceuticals, Biozeus, Topadur Pharma, and others.
Pulmonary Hypertension Pipeline Analysis:
The Pulmonary Hypertension pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Hypertension with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Hypertension Treatment.
- Pulmonary Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pulmonary Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Hypertension market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pulmonary Hypertension drugs and therapies
Pulmonary Hypertension Pipeline Market Drivers
- Rising prevalence of Pulmonary Hypertension worldwide, increasing investment for healthcare infrastructure, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Hypertension Market.
Pulmonary Hypertension Pipeline Market Barriers
- However, high cost associated with the treatment of Pulmonary Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Hypertension Market growth.
Scope of Pulmonary Hypertension Pipeline Drug Insight
- Coverage: Global
- Key Pulmonary Hypertension Companies: Topadur Pharma, Centessa Pharmaceuticals, Ribomic, Gmax Biopharm, ATXA Therapeutics, Aerami Therapeutics, PhaseBio Pharmaceuticals, Altavant Sciences, Respira Therapeutics, Pharmosa Biopharm, Merck, Arena Pharmaceuticals/United Therapeutics, Bial – Portela C S.A., Respira Therapeutics, Gmax Biopharm, Aerami Therapeutics, Centessa Pharmaceuticals, and others
- Key Pulmonary Hypertension Therapies: TOP V122, MGX292, RBM-011, Getagozumab, NTP42, AER-901, Pemziviptadil (PB1046), Rodatristat Ethyl, RT234, L606, Sotatercept, Ralinepag, Zamicastat, RT234, GMA301, AER-901, MGX 292, and others
- Pulmonary Hypertension Therapeutic Assessment: Pulmonary Hypertension current marketed and Pulmonary Hypertension emerging therapies
- Pulmonary Hypertension Market Dynamics: Pulmonary Hypertension market drivers and Pulmonary Hypertension market barriers
Request for Sample PDF Report for Pulmonary Hypertension Pipeline Assessment and clinical trials
Table of Contents
1. Pulmonary Hypertension Report Introduction
2. Pulmonary Hypertension Executive Summary
3. Pulmonary Hypertension Overview
4. Pulmonary Hypertension- Analytical Perspective In-depth Commercial Assessment
5. Pulmonary Hypertension Pipeline Therapeutics
6. Pulmonary Hypertension Late Stage Products (Phase II/III)
7. Pulmonary Hypertension Mid Stage Products (Phase II)
8. Pulmonary Hypertension Early Stage Products (Phase I)
9. Pulmonary Hypertension Preclinical Stage Products
10. Pulmonary Hypertension Therapeutics Assessment
11. Pulmonary Hypertension Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pulmonary Hypertension Key Companies
14. Pulmonary Hypertension Key Products
15. Pulmonary Hypertension Unmet Needs
16 . Pulmonary Hypertension Market Drivers and Barriers
17. Pulmonary Hypertension Future Perspectives and Conclusion
18. Pulmonary Hypertension Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States